1 Institute for Molecular Biotechnology of the Austrian Academy of Sciences, Vienna, Austria Departments of Immunology and Medical Biophysics, University of Toronto, University Health Network, Canada ...
Objectives To develop evidence-based recommendations for management of calcium pyrophosphate deposition (CPPD). Methods A multidisciplinary guideline development group of 15 experts, representing 10 ...
1 Department of Rheumatology, University Medical Centre St Radboud, Nijmegen, The Netherlands 2 Department of Rheumatology, St Maartenshospital, Nijmegen, The Netherlands 3 Department of Medical ...
The first choice for prevention of corticosteroid osteoporosis is a potent oral bisphosphonate—for example, alendronate or risedronate. Intravenous bisphosphonates should be considered for patients ...
BACKGROUND Osteoarthritis (OA) is the most common joint disease encountered throughout Europe. A task force for the EULAR Standing Committee for Clinical Trials met in 1998 to determine the ...
3 Department of Rheumatology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark 4 Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark 5 Department of Rheumatology ...
2 Azienda Zero, Veneto Region, Clinical governance Unit, Padua, Italy 3 Azienda Zero, Veneto Region, Epidemiological Department, Padua, Italy 4 Azienda Zero, Veneto Region, Clinical governance Unit, ...
Correspondence to Professor Lisa K Stamp, Department of Medicine, University of Otago, Christchurch, P.O. Box 4345, Christchurch 8014, New Zealand; lisa.stamp{at}cdhb.health.nz Objectives To determine ...
Background: RTX-GRT7039 (resiniferatoxin; RTX), is a potent and selective agonist of the transient receptor potential vanilloid 1 (TRPV1) being developed for treatment of pain related to knee ...
Background The SELENA flare index (SFI) has functioned well in clinical and clinical trial settings (1), but has the limitation that it classifies only severe versus combined mild/moderate flares.
The multiple rheumatological faces of PsA (or PsA is more than just poly-arthritis? - Consequences for management in daily practice) ...
F8: Back to the future: how to mix the old and new treatments for SLE, Sjögren's and APS ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results